Benedikt Schaefgen1, Marija Juskic1, Madeleine Hertel2, Richard G Barr3, Marcus Radicke2, Anne Stieber4, André Hennigs1, Fabian Riedel1, Christof Sohn1, Joerg Heil1, Michael Golatta5. 1. Department of Gynecology and Obstetrics, University Breast Unit, Heidelberg, Germany. 2. Siemens Healthcare GmbH, Forchheim, Germany. 3. Northeastern Ohio Medical University and Southwoods Imaging, Youngstown, OH, USA. 4. Department of Radiology, University Breast Unit, Heidelberg, Germany. 5. Department of Gynecology and Obstetrics, University Breast Unit, Heidelberg, Germany. Michael.Golatta@med.uni-heidelberg.de.
Abstract
PURPOSE: The FUSION-X-US-II prototype was developed to combine 3D-automated breast ultrasound (ABUS) and digital breast tomosynthesis in a single device without decompressing the breast. We evaluated the technical function, feasibility of the examination workflow, image quality, breast tissue coverage and patient comfort of the ABUS device of the new prototype. METHODS: In this prospective feasibility study, the FUSION-X-US-II prototype was used to perform ABUS in 30 healthy volunteers without history of breast cancer. The ABUS images of the prototype were interpreted by a physician with specialization in breast diagnostics. Any detected lesions were measured and classified using BI-RADS® scores. Image quality was rated subjectively by the physician and coverage of the breast was measured. Patient comfort was evaluated by a questionnaire after the examination. RESULTS: One hundred and six scans were performed (61 × CC, 23 × ML, 22 × MLO) in 60 breasts. Image acquisition and processing by the prototype was fast and accurate. Breast coverage by ABUS was approximately 90.8%. Sixteen breast lesions (all benign, classified as BIRADS® 2) were identified. The examination was tolerated by all patients. CONCLUSION: The FUSION-X-US-II prototype allows a rapid ABUS scan with mostly high patient comfort. Technical developments resulted in an improvement of quality and coverage compared to previous prototype versions. The results are encouraging for a test of the prototype in a clinical setting in combination with tomosynthesis.
PURPOSE: The FUSION-X-US-II prototype was developed to combine 3D-automated breast ultrasound (ABUS) and digital breast tomosynthesis in a single device without decompressing the breast. We evaluated the technical function, feasibility of the examination workflow, image quality, breast tissue coverage and patient comfort of the ABUS device of the new prototype. METHODS: In this prospective feasibility study, the FUSION-X-US-II prototype was used to perform ABUS in 30 healthy volunteers without history of breast cancer. The ABUS images of the prototype were interpreted by a physician with specialization in breast diagnostics. Any detected lesions were measured and classified using BI-RADS® scores. Image quality was rated subjectively by the physician and coverage of the breast was measured. Patient comfort was evaluated by a questionnaire after the examination. RESULTS: One hundred and six scans were performed (61 × CC, 23 × ML, 22 × MLO) in 60 breasts. Image acquisition and processing by the prototype was fast and accurate. Breast coverage by ABUS was approximately 90.8%. Sixteen breast lesions (all benign, classified as BIRADS® 2) were identified. The examination was tolerated by all patients. CONCLUSION: The FUSION-X-US-II prototype allows a rapid ABUS scan with mostly high patient comfort. Technical developments resulted in an improvement of quality and coverage compared to previous prototype versions. The results are encouraging for a test of the prototype in a clinical setting in combination with tomosynthesis.
Authors: Rachel F Brem; László Tabár; Stephen W Duffy; Marc F Inciardi; Jessica A Guingrich; Beverly E Hashimoto; Marla R Lander; Robert L Lapidus; Mary Kay Peterson; Jocelyn A Rapelyea; Susan Roux; Kathy J Schilling; Biren A Shah; Jessica Torrente; Ralph T Wynn; Dave P Miller Journal: Radiology Date: 2014-10-17 Impact factor: 11.105
Authors: Wendie A Berg; Jeffrey D Blume; Jean B Cormack; Ellen B Mendelson; Daniel Lehrer; Marcela Böhm-Vélez; Etta D Pisano; Roberta A Jong; W Phil Evans; Marilyn J Morton; Mary C Mahoney; Linda Hovanessian Larsen; Richard G Barr; Dione M Farria; Helga S Marques; Karan Boparai Journal: JAMA Date: 2008-05-14 Impact factor: 56.272